Homocysteine (Hcy) is an intermediate metabolite of methionine metabolism, and a large number of studies have found that Hcy is closely related to cardiovascular diseases. MicroRNA(miRNA) is a large class of short-chain non-coding RNA, it has been confirmed in a variety of diseases that miRNA disorder can lead to disease progression, such as immune disorders, diabetes, epilepsy, cancer, etc. At present, miRNA is considered as a new treatment strategy for cardiovascular diseases due to its crucial role in the cardiovascular system. The current study has confirmed that both Hcy and miRNA are risk factors for cardiovascular disease, but the role of Hcy and miRNA interaction in cardiovascular disease remains to be elucidated. This paper briefly reviews the progress and potential clinical application of Hcy regulated miRNA in cardiovascular diseases.